SCHEDULE: Redmile Group Discloses Nurix Therapeutics Stake

Redmile Group, LLC, Jeremy C. Green, and RedCo II Offshore SPV LLC have updated their beneficial ownership filings for Nurix Therapeutics, Inc., collectively holding 8.1% and 3.5% of the common stock.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership of Nurix Therapeutics, Inc. common stock.
• Redmile Group, LLC, Jeremy C. Green, and RedCo II Offshore SPV LLC are the reporting persons.
• Redmile Group, LLC and Jeremy C. Green collectively beneficially own 8,782,256 shares, representing 8.1% of the class.
• RedCo II Offshore SPV LLC beneficially owns 3,712,546 shares, representing 3.5% of the class.
• The shares owned by Redmile Group, LLC and Jeremy C. Green include 4,073,787 shares of common stock and 4,708,469 shares issuable upon exercise of pre-funded warrants.
• The shares owned by RedCo II Offshore SPV LLC include 831,404 shares of common stock and 2,881,142 shares issuable upon exercise of warrants.
• The percentages are calculated based on 103,781,683 shares of common stock outstanding as of June 30, 2026, as reported by the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral filing, primarily an update on beneficial ownership rather than a strategic or financial performance announcement.

Positives

• The reporting persons collectively hold a significant stake (8.1%) in Nurix Therapeutics, Inc., which could indicate confidence in the company's future prospects.
• The filing clarifies the beneficial ownership structure, providing transparency to investors.

Negatives

• The filing does not contain any financial performance data or strategic updates, limiting its immediate impact on investment decisions.
• The reporting persons disclaim beneficial ownership beyond their pecuniary interest, which is standard but can be noted.

Risks

• The filing does not explicitly mention any risks associated with the investment or the company's operations.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• Redmile and Mr. Green each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest in such securities, if any.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically represent passive investments by institutional investors. Redmile Group is known for its significant investments in the biotechnology sector, and this filing reflects their ongoing engagement with Nurix Therapeutics.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant beneficial ownership, potentially influencing market perception.
• Management: Awareness of substantial investor holdings and their potential influence.

Next Steps

• The reporting persons will continue to monitor their beneficial ownership in Nurix Therapeutics, Inc.

Key Dates

Keywords

Nurix Therapeutics, Redmile Group, Beneficial Ownership, Schedule 13G, Investment Vehicles, Warrants, Common Stock